Hedge Fund Manager Attacked Over Biotech Stock Short Sales

Law360, New York (July 9, 2012, 4:31 PM EDT) -- A government watchdog group on Monday asked the U.S. Attorney in New York City to investigate a hedge fund manager over allegations that he manipulated the price of biotechnology and pharmaceutical stocks by lobbying the U.S. Food and Drug Administration and by blogging.

Citizens for Responsibility and Ethics in Washington said that Martin Shkreli, chief investment officer at MSMB Capital Management LLC, had profited by arguing against drugs and other items before the FDA and criticizing the companies that made them on his blog, allegations that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.